Nature Cancer: Non-small cell lung cancer immunotherapy effect prediction marker - HLA-B44 supertype

Human lewd cell antigens (HLA)-B are considered to be the main determinants of disease prognosis differences, and recent evidence suggests that they play a role in the efficacy of immuno-checkpoint blocking therapy (ICB).
HLA-B44 supertype, which is characterized by a pocket with electro-positive binding, giving priority to the display of negatively charged amino acid anchoring peptides, is associated with improving the survival rate of melanoma ICC treatment1.
, however, this correlation was not seen in non-small cell lung cancer (NSCLC) treated with ICC.
a research paper published in the journal Nature Cancer by the Edward Garon team, entitled: Mutational landscape influences immunotherapy outcomes with among patients with non-small-celllung cancer with human leukocyte antigen supertype B44, explores whether HLA-B44 supertypes affect the efficacy of immuno-checkpoint blocking therapy (ICB) in non-small cell lung cancer.
the study, mutations that lead to glutamate replacement are more common in melanoma than non-small cell lung cancer, based on a genetic mutation map.
In addition, B44 was layered based on the presence of somatic cell mutations that cause negatively charged glutamate anchorage points, and it was determined that the benefits of immuno-checkpoint blocking therapy in patients with non-small cell lung cancer were similar to between melanoma.
these findings could improve the assessment of HLA-related results and predict the benefits of blocking treatment at immune checkpoints in patients with B44.
team sequenced all-exosomes (WES) in 67 patients treated with Parmesan monotherapy at ucla, obtained HLA parting, tumor mutation load (TMB), and newborn antigens, and used the NSCLC and melanoma immunotherapy queues at the Dana Farber Cancer Institute as external validation.
, the researchers analyzed the semi-inhibitory concentration (IC50) between HLA-B44 supertypes and new antigens through in-body tests.
study found that HLA-B44 supertypes were effective in predicting PFS and OS for ICC treatment in UCLA-NSCLC, DF-NSCLC, and DF-melanoma queues, and that patients with HLA-B44 supertypes had longer PFS and OS than non-carriers.
Os and PFS based on the new charged table sequence analyzed the prognosis effects of HLA-B44 supertypes on NSCLC and melanoma immunotherapy in general, the study found that HLA-B44 supertypes can be used for NSCLC immunotherapy efficacy prediction, similar to their function in melanoma, but other HLA supertypes have yet to be further verified.
。